Jan 1, 2021
But if rivaroxaban is ’in’, is DAPT ’out’?
The introduction of direct oral anticoagulants (DOACs) in 2010 significantly changed clinical algorithms for prevention of VTE and stroke, as well as management of atrial fibrillation. In this report, which was initially published March 29, 2020, researchers presented findings that support a role for rivaroxaban in revascularization procedures in patients with PAD. BreakingMED is republishing this report as part of its year end clinical review series.
Findings from a trial of more than 6,564 patients undergoing revascularization procedures for peripheral artery disease are likely to change clinical practice, signaling a death knell for dual antiplatelet therapy while boosting the use of direct oral anticoagulant (DOAC) therapy in these patients.